Private Practice, Clinica Oftalmologica de Antioquia, CLOFAN, Medellín, Colombia.
Department of Ophthalmology, Universidad Pontificia Bolivariana, Medellín, Colombia; Research Department at Oftalmosalud Instituto de Ojos, Lima, Peru.
Am J Ophthalmol. 2020 Dec;220:170-176. doi: 10.1016/j.ajo.2020.07.032. Epub 2020 Jul 28.
We sought to evaluate the visual, refractive, and biomicroscopic findings pre- and posttreatment of observed anterior stromal necrosis (ASN) after long-term Intacs intracorneal ring segment (ICRS) implantation.
Consecutive interventional case series.
All consecutive patients implanted with Intacs ICRS at a single center by 1 of the authors between October 2006 and October 2011 with a minimum follow-up time of 5 years were included. All Intacs were implanted using the Prolate system console and instrumentation from Addition Technology Inc (Chicago, Illinois, USA). The slit lamp, refractive, and visual findings and the management of those patients are described in detail. The primary outcome measures included the size of the epithelial defect overlying the Intacs body, the intended implantation depth measured by high-magnification slit lamp photography, and the management of the cases described in detail. The percentage of eyes with ASN out of those that reached the 5-year follow-up is reported.
One hundred twenty-seven eyes (84 patients) were implanted with 215 ICRSs during the study period, and 77.16% (98/127) eyes had a follow-up of ≥5 years, out of which 9 eyes (7 patients) had ASN corresponding to at least 9.18% (95% confidence interval 4.29%-16.72%). The mean ± standard deviation time between implantation and ASN diagnosis was 10.5 ± 1.3 years.
After 5 years of implantation, INTACS-treated eyes could present with an ASN over the ICRS body. Longer-term follow-up of patients implanted with INTACS is important to monitor if this complication keeps occurring over time.
我们旨在评估长期 Intacs 角膜内环段（ICRS）植入后观察到的前基质坏死（ASN）的治疗前后的视力、屈光度和眼前节的发现。
连续的干预性病例系列。
所有连续患者由一位作者在 2006 年 10 月至 2011 年 10 月期间在单中心接受 Intacs ICRS 植入，并进行了至少 5 年的随访。所有 Intacs 均采用 Addition Technology Inc（美国伊利诺伊州芝加哥）的 Prolate 系统控制台和器械植入。详细描述了裂隙灯、屈光和视觉检查结果以及这些患者的处理情况。主要观察指标包括：上皮缺损覆盖 Intacs 体的大小、高倍显微镜下测量的预期植入深度以及详细描述的病例处理。报告了达到 5 年随访的 ASN 眼的比例。
在研究期间，有 127 只眼（84 例患者）接受了 215 个 ICRS 植入，其中 77.16%（98/127）眼的随访时间≥5 年，其中 9 只眼（7 例患者）出现了至少 9.18%（95%置信区间为 4.29%-16.72%）的 ASN。植入与 ASN 诊断之间的平均时间±标准差为 10.5±1.3 年。
植入 5 年后，INTACS 治疗的眼睛可能会在 ICRS 体上出现 ASN。对接受 INTACS 植入的患者进行长期随访对于监测这种并发症是否会随着时间的推移而持续发生非常重要。
